Erythropoietin Promotes the Growth of Tumors Lacking Its Receptor and Decreases Survival of Tumor-Bearing Mice by Enhancing Angiogenesis  by Okazaki, Tatsuma et al.
Erythropoietin Promotes
the Growth of Tumors
Lacking Its Receptor and
Decreases Survival of
Tumor-Bearing Mice by
Enhancing Angiogenesis1
Tatsuma Okazaki2, Satoru Ebihara,
Masanori Asada, Shinsuke Yamanda,
Kaijun Niu and Hiroyuki Arai
Department of Geriatrics and Gerontology, Institute
of Development, Aging and Cancer, Tohoku University,
Seiryo-machi 4-1, Aoba-ku, Sendai 980-8575, Japan
Abstract
Erythropoietin (Epo), a known hematopoietic growth factor, has been reported to promote tumor growth and angio-
genesis in Epo receptor (EpoR)–positive tumors, but its effects on EpoR-negative tumors have not been clearly
shown. Here, we show that Epo accelerates the growth of EpoR-negative tumors by promoting tumor angiogenesis.
Mice were inoculated with Lewis lung carcinoma cells and treated with Epo. Erythropoietin accelerated tumor
growth and increased intratumoral microvessel density, although it did not accelerate Lewis lung carcinoma cell
tumor proliferation in vitro. To observe the direct effect of Epo on endothelial cells, we examined human dermal
microvascular endothelial cells (HMVECs) that expressed EpoR. Erythropoietin induced the proliferation of HMVECs
and protected them from H2O2-induced cell death. Erythropoietin activated the extracellular signal–regulated kinase
signaling pathway and up-regulated the expression of the downstream antiapoptotic protein Bcl-xL in HMVECs.
Moreover, in both the absence and presence of tumors, in vivo treatment of mice with Epo increased circulating
endothelial progenitor cells. To investigate the role of Epo in a primary tumor model, we inoculated the chemical
carcinogen methylcholanthrene (MCA) subcutaneously into mice at two doses, a high or a low dose, which induced
fibrosarcoma, and treated them with Epo. Erythropoietin promoted tumor growth after MCA inoculation at both
doses and decreased the overall survival of the mice inoculated with the high-dose MCA. However, Epo did not in-
crease the incidence of fibrosarcoma at either dose. Lewis lung carcinoma cells andMCA-induced fibrosarcomas did
not express EpoR. These results suggest that Epo accelerates the growth of tumors that lack EpoR expression by
promoting tumor angiogenesis.
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Introduction
Hematopoietic growth factors are often used in intensive cancer
chemotherapy to help overcome myelosuppression, a reduction in
blood cell numbers caused by anticancer treatment. However, recent
studies in mice suggest that hematopoietic growth factors such as
macrophage colony-stimulating factor (M-CSF) and granulocyte
colony-stimulating factor (G-CSF) can cause tumor growth by pro-
moting angiogenesis [1–3], which supplies blood to solid tumors
[4,5]. Erythropoietin (Epo) is one of the hematopoietic growth fac-
tors often used in cancer treatment. It normally regulates the prolif-
eration, survival, and differentiation of the erythroid lineage, but
recent studies have shown that Epo can act on nonhematopoietic or-
gans including solid tumors [6]. The effect of Epo on the survival
rate of cancer patients seems variable: Epo decreases the survival of
cancer patients with head and neck, metastatic breast, or non–small
cell lung cancer [7–9], but by contrast, erythropoiesis-stimulating
agents (ESAs), which include Epo, does not reduce the survival rate
of patients with small cell lung cancer [10]. In 2007, the Food and
Drug Administration convened a meeting to discuss the risks of ad-
ministrating ESAs to cancer patients. However, no clear conclusion
was reached, and the Food and Drug Administration simply advised
caution in the use of ESAs [10]. A clearer understanding of Epo’s
effect on tumor growth is therefore urgently needed to help clinicians
decide whether to prescribe Epo to their cancer patients.
One way in which Epo could trigger tumor growth is by acting
directly on the tumor cells because many tumor cells express the
Epo receptor (EpoR). However, the response of EpoR-expressing
tumor cells to Epo varies. Some studies found that Epo treatment
can increase tumor cell numbers in vitro [11–13], although others
found no effect [6]. In vivo studies found that blocking Epo function
can inhibit the progression of certain tumors [13,14], although other
studies found that Epo treatment had no effect on tumor growth
[15]. Whereas the effect of Epo on EpoR-positive tumors is still
controversial, even less is known about the effects of Epo on EpoR-
negative tumors.
Several studies suggest that Epo could act indirectly on tumor
growth. For instance, Epo has been reported to act on tumor angio-
genesis [6,16] and some studies have shown a direct effect of Epo on
some endothelial cells (ECs) [17,18]. Moreover, Epo can increase the
number of circulating endothelial progenitor cells (EPCs) in tumor-
free humans and mice [19,20]. However, although EPCs have re-
cently been found to contribute to tumor vessel formation [21,22],
the effect of Epo on circulating EPCs has not been reported in can-
cer models. In addition, because most previous studies used EpoR-
positive tumors, they could not distinguish between a direct effect of
Epo on tumors and an indirect effect through angiogenesis.
In the present study, we examined the effect of Epo on two types
of EpoR-negative tumors: implanted Lewis lung carcinoma cells
(LLCs) and primary fibrosarcoma induced by a chemical carcinogen
methylcholanthrene (MCA) [23]. We found that Epo could trigger
growth of these tumors by stimulating angiogenesis and examined
which pathway responded to Epo in the ECs.
Materials and Methods
Cell Culture
Lewis lung carcinoma cells, H9c2 cells, and KLN 205 cells were
purchased from American Type Culture Collection (Manassas, VA).
Lewis lung carcinoma cells were cultured in a high-glucose Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum (FCS) and
100 μg/ml kanamycin. H9c2 cells were cultured in a high-glucose
Dulbecco’s modified Eagle’s medium containing 10% FCS, 100 U/ml
penicillin, and 0.1 mg/ml streptomycin. H9c2 cells were differenti-
ated to H9c2 myotubes as previously shown [24]. KLN 205 cells
were cultured in minimum essential medium containing 10% FCS,
1% nonessential amino acids, and 100 μg/ml kanamycin. Normal
adult human dermal microvascular endothelial cells (HMVECs),
originally derived from foreskins, and human umbilical vein en-
dothelial cells (HUVECs) were purchased from Kurabo (Osaka,
Japan) and were cultured in HuMedia-MvG medium (Kurabo).
Lewis Lung Carcinoma Cell Tumor Model
Lewis lung carcinoma cells (3 × 105 cells per mouse) were injected
subcutaneously into the hind flank of male C57BL/6 mice (6–
9 weeks old) on day 0. Tumor size was quantified daily as width2 ×
length × 0.52 [1]. For tumor growth rate models, human recombi-
nant Epo (epoetin beta, 200 IU/kg; Chugai Seiyaku, Tokyo, Japan)
was injected into mice subcutaneously once a week from day 1.
The mice were killed on day 25 (total four Epo injections per
mouse). For the culture assay of EPCs, Epo was injected subcuta-
neously for 3 days daily from day 18, and the mice were killed on
day 21. Controls were subcutaneously injected with phosphate-
buffered saline (PBS).
Histology
When the diameter of the tumors reached approximately 1.2 cm,
tumors were fixed in 10% formalin, embedded in paraffin and
sectioned [1]. Control mice were killed on day 21, and the Epo-
treated mice were killed on day 19 (total three Epo injections). The
sections were stained with hematoxylin and eosin (H&E). The
intratumoral microvessel density was determined as previously de-
scribed by immunohistochemical staining with polyclonal anti–
human factor VIII–related antigen antibody (DakoCytomation,
Carpinteria, CA) [1,25,26].
Cell Proliferation and Cell Death Assays
The assays were performed as previously shown [27]. In short,
LLCs (5 × 103 cells) were incubated with 0, 0.2, 1, or 5 IU/ml
Epo for 48 hours. Human dermal microvascular endothelial cells
(3 × 103 cells) were incubated with 0, 0.008, 0.04, 0.2, or 1 IU/ml
Epo for 36 or 48 hours. Then, the cell numbers were determined by
water-soluble tetrazolium (WST) assay using a Cell Counting Kit
(Dojindo, Tokyo, Japan). For cell death assays, HMVECs were incu-
bated with 0, 0.04, 0.2, or 1 IU/ml Epo for 16 hours. Then, the cells
were stimulated with H2O2 for 8 hours. The WST assay determined
the cell viability.
Flow Cytometry
Fluorescein isothiocyanate–labeled anti-CD34 and purified rat
anti-CD144 (VE-cadherin) antibodies were purchased from BD
Pharmingen (San Diego, CA), PE-labeled anti-EpoR was purchased
from DakoCytomation, and control rat IgG2a was purchased from
eBioscience (San Diego, CA). Flow cytometry for EPCs was per-
formed as previously shown [1]. For EpoR detection, the cells were
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first incubated with unlabeled anti-CD16/32 mAb (eBioscience) and
then with the anti-EpoR antibody. Flow cytometry was performed
with a FACScan (BD Bioscience, San Jose, CA), and data were an-
alyzed with CellQuest software (BD Bioscience) [1].
Western Blot Analysis
Western blot analysis was performed as previously shown [28].
Human dermal microvascular endothelial cells (1 × 106 cells) were stim-
ulated with Epo (1 IU/ml) for indicated periods. Methylcholanthrene-
induced fibrosarcoma cells (3 × 106 cells) or LLCs (2 × 106 cells)
were plated onto a culture dish, cultured overnight, and lysed. H9c2
cells were differentiated to H9c2 myotubes, stimulated with M-CSF
(100 ng/ml) for 10 minutes, and lysed as previously shown [24]. HeLa
cell lysates were purchased from Cell Signaling Technology (Beverly,
MA). The cell lysates were subjected to gel electrophoresis and trans-
ferred onto polyvinylidene difluoride membranes (Millipore, Billerica,
MA). The membranes were blotted with antibodies to phospho–
extracellular signal–regulated kinase (ERK), phospho-Akt, phospho–
signal transducer and activator of transcription 5 (Stat5), Bcl-xL (Cell
Signaling Technology), or EpoR (Santa Cruz Biotechnology, Santa
Cruz, CA). The membranes blotted with antibodies to detect phos-
phorylation were then reblotted with antibodies to total ERK, Akt,
and Stat5 (Cell Signaling Technology).
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
Methylcholanthrene-induced fibrosarcoma cells (3 × 106 cells), LLCs
(2 × 106 cells), or KLN 205 cells (3 × 106 cells) were plated onto a cul-
ture dish and cultured overnight, and total RNA was isolated using
RNAzol B reagent (Tel-Test, Friendswood, TX). Conventional reverse
transcription–polymerase chain reaction (RT-PCR) was performed as
previously shown [1] using primers as previously described [29].
Culture Assay of Circulating EPCs
Mononuclear cells were isolated, cultured, characterized, and
counted as previously described [30] with some modifications [1].
Fluorescent microscopy identified cultured circulating EPCs as
double-positive cells for acetylated low-density lipoprotein–Dil com-
plex (Dil-acLDL; Molecular Probes, Eugene, OR) and fluorescein
isothiocyanate-labeled lectin from Ulex europaus (Sigma-Aldrich,
Figure 1. Epo accelerates tumor growth in vivo but not in vitro. (A)
Mice were inoculated with LLCs on day 0 and treated with Epo or
PBS from day 1 once a week. Erythropoietin significantly accel-
erated tumor growth (n = 8 per group, *P < .03). (B) Lewis lung
carcinoma cells (5 × 103 cells) were cultured with the indicated
amounts of Epo for 48 hours. Water-soluble tetrazolium assay de-
termined the cell number. Shown is representative of three inde-
pendent experiments.
Figure 2. Epo increases tumor microvessel density in vivo. (A–D) Mice were inoculated with LLCs on day 0 and killed when the diameter
of the tumors reached 1.2 cm. Control mice (A and B) were killed on day 21, and Epo-treated mice (C and D) were killed on day 19 (total
three Epo injections). Sections were stained with H&E (A and C) and anti–factor VIII–related antigen antibody (B and D); scale bar,
100 μm. Images show one representative mouse of eight in each group. (E) Epo significantly increased microvessel density in tumors
(n = 8 per group, *P < .01).
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St. Louis, MO). Two independent investigators evaluated the num-
ber of double-positive cells by counting three randomly selected
high-power fields.
Methylcholanthrene-Induced Fibrosarcoma
Six-week-old male C57BL/6 mice were injected subcutaneously
into the hind flank with 25 (low dose) or 100 μg (high dose) of
3-MCA (Sigma-Aldrich) in 0.1 ml of maize oil. Development of
the fibrosarcoma was assessed periodically for 100 to 150 days. Tu-
mors more than 2 mm in diameter were recognized as positive. Tu-
mor size was quantified as described in the Lewis Lung Carcinoma
Cell Tumor Model section. For the MCA-induced fibrosarcoma cell
isolation, when the diameter of 100-μg MCA-induced fibrosarcoma
reached 1 cm, the mice were killed and the tumors were removed
aseptically. Tumors were cut into small pieces and treated with col-
lagenase (Sigma type IV) at 37°C for 1 hour. Clumps were removed,
and single cells were cultured in RPMI 1640 medium supplemented
with 10% FCS and 2 mM L-glutamine.
Data Analysis
Data are shown as mean ± SD. Statistical analysis was performed
using analysis of variance with Fisher’s least significant difference test.
Statistical analysis of the overall survival of MCA-induced fibrosarcoma-
bearing mice was performed using Mann-Whitney U test. P values <
.05 were considered as significant.
Results
Erythropoietin Accelerates Tumor Growth In Vivo
But Not In Vitro
To test the effect of Epo in vivo, we inoculated LLCs into mice
subcutaneously on day 0 and injected Epo or PBS into the mice once
a week starting at day 1. Erythropoietin significantly accelerated tu-
mor growth (Figure 1A). To test whether this growth might reflect a
direct effect of Epo on LLCs, we examined the response of LLCs to
Epo in vitro. We found that Epo did not increase LLC proliferation
in vitro (Figure 1B). Because the FCS might contain some growth
factors that made high-growing background, we examined the re-
sponse of LLCs to Epo under low-FCS culture medium condition
that contained 5% FCS. We found that Epo did not increase LLC
proliferation under this condition (data not shown). The effect of
Epo on LLC tumor growth therefore seems to be indirect.
Erythropoietin Increases Tumor Microvessel Density In Vivo
To analyze the mechanism of tumor growth acceleration by Epo, we
stained the tumors with H&E and found that the number of tumor
blood vessels was higher in Epo-treated mice than in PBS-treated mice
(Figure 2, A and C ). To quantify tumor angiogenesis, we stained
tumors with an antibody against the factor VIII–related antigen, a
blood vessel marker (Figure 2, B and D) [1,26]. Erythropoietin sig-
nificantly increased microvessel density in tumors (Figure 2E ).
Erythropoietin Promotes Proliferation and Survival of
HMVEC In Vitro, Activates ERK Signaling, and Increases
Bcl-xL Expression
Because Epo promoted tumor angiogenesis, we examined effect of
Epo on ECs more precisely in vitro. We examined EpoR expression
on two types of ECs using FACS analysis. We found EpoR expres-
sion onHMVECs (Figure 3A) but not onHUVECs (data not shown).
Because HMVECs expressed EpoR, we next examined HMVEC
proliferation after various periods of exposure to Epo. Erythropoietin
significantly promoted proliferation of HMVECs at 36 and 48 hours
of exposure (Figure 3B) but not at 24 hours (data not shown). An-
other hematopoietic growth factor, M-CSF, supports the survival of
cardiomyocytes and skeletal muscle cells in the presence of the toxic
dose of H2O2 [24]. Therefore, we examined the effect of Epo on
the survival of HMVECs exposed to H2O2. Erythropoietin signif-
icantly protected HMVECs from H2O2-induced cell death (Fig-
ure 3C ). In erythroid cells, Epo activates cell signaling pathways
such as the Akt pathway, the Janus-associated kinase 2 (Jak2)–Stat5
pathway, and the ERK pathway [31,32]. To elucidate the molecular
mechanisms of Epo-induced proliferation and survival, the activa-
tion status of the ERK, Akt, and Stat5 signaling pathways was in-
vestigated in HMVECs after treatment with Epo. Erythropoietin
activated ERK, as indicated by ERK phosphorylation, although it
did not affect the total ERK protein levels in cell lysates (Fig-
ure 3D). In contrast, Epo did not activate Akt or Stat5 (Figure 3D).
Cell lysates derived from H9c2 myotubes stimulated with M-CSF
and HeLa cells stimulated with IFN-α were used as positive con-
trols for the activated form of Akt and Stat5 respectively (Fig-
ure 3D). Extracellular signal–regulated kinase activation by Epo
up-regulates the antiapoptotic protein Bcl-xL in a leukemia cell
line and in erythroid progenitor cells [33]. Therefore, we examined
Bcl-xL expression in Epo-stimulated HMVECs. Low-level Bcl-xL
expression was detected in HMVECs without Epo stimulation
(Figure 3D). Erythropoietin up-regulated Bcl-xL expression after
12 and 24 hours of exposure (Figure 3D) before Epo has any effect
on cell proliferation. At later time points, Bcl-xL levels kept increas-
ing, but we cannot interpret this increase because of Epo’s effect on
cell proliferation. These results suggest that Epo induces the prolif-
eration and survival of HMVECs by activating ERK and their sur-
vival by up-regulating Bcl-xL.
Erythropoietin Increases the Number of Circulating EPCs in
Tumor-Bearing Mice
We hypothesized that Epo enhanced tumor angiogenesis by in-
creasing the numbers of circulating EPCs in addition to directly
stimulating ECs. To investigate the effects of Epo on the number
of circulating EPCs, mice were injected with Epo for 3 days and cir-
culating EPCs, characterized by Dil-acLDL uptake, lectin binding,
and CD34 and VE-cadherin expression (Figure 4, A and B) [34–
36], were counted. Erythropoietin significantly increased the number
of circulating EPCs (Figure 4C ). We next evaluated the effect of Epo
on circulating EPCs in mice bearing LLCs. Injection of Epo once a
week starting 1 day after LLC inoculation significantly increased the
tumor volume after day 17 (Figure 1A). Previous study showed that a
growing LLC tumor itself increased serum vascular endothelial
growth factor (VEGF) level and the numbers of EPCs [1], which
suggested that when the volume of LLC tumors increased, it could
increase the number of circulating EPCs. To isolate circulating EPCs
from mice bearing a similar volume of LLC tumors, we injected Epo
from day 18 for three consecutive days and isolated EPCs on day 21.
This treatment significantly increased the number of circulating
EPCs (Figure 4D) without significantly affecting tumor size (data
not shown).
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Erythropoietin Promotes Tumor Growth But Does Not
Increase the Incidence of MCA-Induced Fibrosarcoma
and Impairs Overall Survival of Mice Inoculated with
High-Dose MCA
We next investigated whether Epo impaired overall survival and
increased the incidence of primary tumor development after treat-
ment with the chemical carcinogen MCA. We injected 25 (low dose)
or 100 μg (high dose) of MCA into mice and injected Epo once a
week for 100 to 150 days starting 1 day after MCA injection. Eryth-
ropoietin did not significantly increase tumor incidence at either dose
of MCA (Figure 5, A and D). However, it significantly promoted
tumor growth after the onset of the tumors at both doses (Figure 5,
B and E ). Erythropoietin significantly impaired the overall survival
of mice inoculated with the high dose of MCA but not the lower
dose (Figure 5, C and F ). Western blot analysis showed EpoR in
HMVECs but not in MCA-induced fibrosarcoma cells or in LLCs
(Figure 5G ), which was consistent with the result in Figures 1B and
2F. Conventional RT-PCR showed mRNA of EpoR in squamous
carcinoma cell line KLN 205 cells, which Epo significantly increased
proliferation rate in vitro (data not shown), but not in MCA-induced
fibrosarcoma cells or in LLCs (Figure 5H ).
Discussion
In this study, we found that Epo accelerated the growth of EpoR-
negative tumors in vivo by promoting angiogenesis, both in a primary
tumor model (MCA-induced tumor) and a conventional tumor model
(LLC inoculation). Erythropoietin directly increased EC proliferation
and decreased EC death by activating ERK and up-regulating the
downstream antiapoptotic protein Bcl-xL. In addition, Epo increased
the number of circulating EPCs in tumor-bearing mice. In the MCA-
induced primary tumormodel, Epo impaired the overall survival of the
100-μg MCA-inoculated mice but not of the 25-μg MCA-inoculated
mice. However, Epo did not increase MCA-induced tumor incidence.
We have previously reported that other hematopoietic growth fac-
tors other than Epo could accelerate tumor growth by promoting
Figure 3. Epo promotes the proliferation and survival of HMVECs in vitro, activates ERK signaling, and increases Bcl-xL expression. (A)
Human dermal microvascular endothelial cells expressed EpoR. The shaded histogram indicates staining with EpoR, and the blank
histogram indicates staining with control IgG. Shown is representative of two independent experiments. (B) Human dermal microvas-
cular endothelial cells were cultured with indicated amount of Epo for indicated periods, and WST assay determined the cell number.
Erythropoietin (0.04, 0.2, and 1 IU/ml) significantly increased the number of HMVECs (*P < .05). (C) Human dermal microvascular en-
dothelial cells were cultured with indicated amount of Epo for 16 hours and then stimulated with H2O2 for 8 hours. Erythropoietin (0.2
and 1 IU/ml) significantly protected HMVECs from H2O2-induced cell death (*P < .02). (D) Human dermal microvascular endothelial cells
were stimulated with Epo (1 IU/ml) for the indicated periods, and then cell lysates were blotted with antibodies specific for the activated
form of ERK (phospho-ERK), Akt (phospho-Akt), or Stat5 (phospho-Stat5). The membranes were reblotted with antibodies to total ERK,
Akt, or Stat5, respectively. Cell lysates derived from M-CSF–stimulated H9c2 myotubes and IFN-α–stimulated HeLa cells were used as
positive controls for the activated form of Akt and Stat5, respectively (D). Bcl-xL expression was confirmed by the specific antibody.
Shown is representative of two independent experiments.
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angiogenesis. Macrophage colony-stimulating factor up-regulated
serum concentration of VEGF, a potent angiogenic factor [1], and
G-CSF increased the number of a type of endothelial cell precursors
known as Gr1+CD11b+ cells [2] and promoted tumor angiogenesis
and growth in mice. Unlike these hematopoietic growth factors, Epo
did not increase VEGF or Gr1+CD11b+ cell numbers in mice (data
not shown). However, we showed that Epo could act on ECs directly.
Erythropoietin significantly impaired the overall survival of mice
inoculated with the higher dose but not the lower dose of MCA. This
difference might be due to the insufficient number of tumor-positive
mice in 25-μg MCA low-dose groups. The high dose of MCA induced
5 to 6 tumor-positive mice among 10 mice, whereas the 25-μg
dose induced only 3 tumor-positive mice among 10 mice. Therefore,
to analyze the overall survival, the number of tumor-positive mice in
low-dose MCA-inoculated groups might be insufficient.
To our knowledge, our study is the first to examine the effect of
Epo on HMVECs. Our observations suggest that different ECs re-
spond to Epo in different manners. For instance, a previous study
using EA.hy926 endothelial cells, which are derived from the fusion
of HUVEC with A549 lung carcinoma cells, showed that Epo acti-
vated Jak2 [17]. Instead of Jak2, we examined its downstream effector
Stat5 and found that it was not activated by Epo in HMVECs, sug-
gesting that Epo does not activate Jak2 in these cells. Very recently,
another study showed that Epo activated Akt and ERK in HUVECs
[18]. By contrast, we could only find evidence for ERK activation
after Epo treatment of HMVECs. Interestingly, we could not de-
tect EpoR on HUVECs we looked at by FACS analysis (data not
shown), whereas we could detect it on HMVECs. Consistent with
this finding, Epo treatment accelerated the proliferation of HMVECs
but not of HUVECs (data not shown). Difference in culture con-
ditions or in the source of HUVECs might explain why we failed
to detect any response from HUVECs to Epo. Further experiments
are required for pursuing the effect of Epo on ECs using other types
of ECs.
Furthermore, our study shows that Epo increases the number of
circulating EPCs in tumor-bearing mice. The role of circulating
EPCs in tumor angiogenesis has been controversial. Using bone mar-
row transplantation, some studies reported large contributions of cir-
culating EPCs to tumor angiogenesis, but other studies reported that
these contributions were negligible [22]. Moreover, another study
showed that bone marrow–derived cells mainly contributed to the
formation of periendothelial vascular mural cells but not to the for-
mation of endothelial cells [37]. On the basis of our observations, we
suggest that both a direct effect of Epo on ECs and the mobilization
of circulating EPCs by Epo contribute to Epo-induced tumor an-
giogenesis. However, we could not determine the extent of the con-
tribution of circulating EPCs to Epo-induced tumor angiogenesis.
Further study is required for identifying this issue.
Figure 4. Epo increases the number of circulating EPCs in tumor-bearing mice. (A) Mononuclear cells were isolated from peripheral
blood and cultured. Fluorescence microscopy determined Dil-acLDL uptake (left panel) and lectin binding (middle panel) of adherent
cells. Double-positive cells (merge) were considered as cultured circulating EPCs (right panel). (B) Expression of CD34 and VE-cadherin
on cultured circulating EPCs. The shaded histograms indicate staining with Abs to CD34 or VE-cadherin, and the blank histograms
indicate background staining with control IgG. (C and D) Mice were injected with Epo for 3 days daily and were then killed (C). Mice
were inoculated with LLCs on day 0, injected with Epo for 3 days daily from day 18, and killed on day 21 (D). Mononuclear cells (4 ×
106 cells per mouse) were isolated from peripheral blood and cultured. Adherent Dil-acLDL and lectin double-positive cells were
counted. Erythropoietin significantly increased the number of double-positive cells (n = 8 per group, *P < .01).
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The effect of Epo on EpoR-negative tumors seems very dose-
dependent. Whereas administering 200 IU/kg once a week increased
the rate of tumor growth, administering 2000 IU/kg once a week
had no detectable effect on tumor growth in our mice models (data
not shown). A large dose of Epo can cause thromboembolic disease
[10]. It is therefore possible that the 2000-IU/kg injection, which is
20 times the recommended dose, causes thromboembolism in tumor
blood vessels, impairing blood supply and preventing acceleration of
the tumor growth. The 200-IU/kg once a week injection is two times
the recommended dose for humans. Therefore, we suggest proceed-
ing with caution while administrating Epo to cancer patients.
We performed immunohistochemical analysis of LLC tumors and
MCA-induced fibrosarcomas but could not obtain clear staining. As
a previous study reported limited use of anti-EpoR antibodies for im-
munohistochemical analysis [38], this analysis will be performed
when an antibody suitable for mice EpoR immunohistochemical
analysis is available.
In summary, Epo directly protected ECs, stimulated EC prolifera-
tion, and increased the number of circulating EPCs. Erythropoietin
promoted tumor growth and angiogenesis in EpoR-negative tumors
and impaired overall survival of the primary tumor-bearing mice.
The effect of Epo on tumor progression might include other mecha-
nisms. However, our results suggest that clinicians should be careful
while using Epo, even with patients carrying EpoR-negative tumors.
Acknowledgments
The authors thank Peter Baluk, Hiroya Hashizume, and Francoise
Chanut for helpful comments and correcting the manuscript.
References
[1] Okazaki T, Ebihara S, Takahashi H, Asada M, Kanda A, and Sasaki H (2005).
Macrophage colony-stimulating factor induces vascular endothelial growth fac-
tor production in skeletal muscle and promotes tumor angiogenesis. J Immunol
174, 7531–7538.
[2] Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, and Yamaya M (2006).
Granulocyte colony-stimulating factor promotes tumor angiogenesis via increas-
ing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer an-
imal models. Int Immunol 18, 1–9.
Figure 5. Epo promotes tumor growth but does not increase the incidence of MCA-induced fibrosarcoma and impairs overall survival of
mice inoculated with high-dose MCA. Mice were subcutaneously inoculated with 25 (low dose) or 100 μg (high dose) of MCA into the
hind flank on day 0, treated with Epo or PBS from day 1 once a week, and observed for fibrosarcoma development during the course of
100 to 150 days (n = 10 mice per group). (A and D) Percentages of mice with tumors are shown. (B and E) Tumor volumes after the
onset of tumor development are shown (n = 3–6 per group). Erythropoietin significantly accelerated tumor growth (*P < .03). (C and F)
Overall survival of mice is shown. Erythropoietin significantly decreased overall survival of 100-μg MCA inoculated mice but not of 25-μg
MCA-inoculated mice (**P < .04). (G) Cell lysates were isolated from MCA-induced fibrosarcoma, LLCs, or HMVECs and blotted with
specific antibody for EpoR. Methylcholanthrene-induced fibrosarcoma or LLC did not express EpoR. (H) Total RNA was isolated from
MCA-induced fibrosarcoma, LLCs, or KLN 205 cells, and conventional RT-PCR was performed for EpoR and S16. KLN 205 cells ex-
pressed mRNA of EpoR but MCA-induced fibrosarcoma or LLCs did not.
938 Epo Promotes Growth of Tumors Lacking Its Receptor Okazaki et al. Neoplasia Vol. 10, No. 9, 2008
[3] Natori T, Sata M, Washida M, Hirata Y, Nagai R, and Makuuchi M (2002). G-
CSF stimulates angiogenesis and promotes tumor growth: potential contribution
of bone marrow–derived endothelial progenitor cells. Biochem Biophys Res Com-
mun 297, 1058–1061.
[4] Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other dis-
ease. Nat Med 1, 27–31.
[5] Ferrara N and Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature
438, 967–974.
[6] Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, and Dewhirst MW
(2006). Erythropoietin biology in cancer. Clin Cancer Res 12, 332–339.
[7] Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer
KT, Burger U, Dougherty C, et al. (2003). Erythropoietin to treat head and neck
cancer patients with anaemia undergoing radiotherapy: randomised, double-
blind, placebo-controlled trial. Lancet 362, 1255–1260.
[8] Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S,
Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, et al. (2005). Maintain-
ing normal hemoglobin levels with epoetin alfa in mainly nonanemic patients
with metastatic breast cancer receiving first-line chemotherapy: a survival study.
J Clin Oncol 23, 5960–5972.
[9] Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman
B, Roa W, Mulroy L, Rudinskas L, et al. (2007). Randomized, double-blind,
placebo-controlled trial of erythropoietin in non–small-cell lung cancer with
disease-related anemia. J Clin Oncol 25, 1027–1032.
[10] Khuri FR (2007). Weighing the hazards of erythropoiesis stimulation in patients
with cancer. N Engl J Med 356, 2445–2448.
[11] Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, and Verma A
(2001). Erythropoietin and erythropoietin receptor expression in human cancer.
Cancer Res 61, 3561–3565.
[12] Westenfelder C and Baranowski RL (2000). Erythropoietin stimulates prolifer-
ation of human renal carcinoma cells. Kidney Int 58, 647–657.
[13] Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M,
Hashimoto M, Musha T, Ogawa K, et al. (2003). Erythropoietin regulates tu-
mour growth of human malignancies. Carcinogenesis 24, 1021–1029.
[14] Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T,
Masuda S, Nagao M, Sasaki R, et al. (2001). Inhibition of erythropoietin signal-
ling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer
84, 836–843.
[15] Hardee ME, Kirkpatrick JP, Shan S, Snyder SA, Vujaskovic Z, Rabbani ZN,
Dewhirst MW, and Blackwell KL (2005). Human recombinant erythropoie-
tin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 93,
1350–1355.
[16] Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo
T, Nagao M, Sasaki R, et al. (2002). Erythropoietin is involved in growth and
angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis
23, 1797–1805.
[17] Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P, Nico B, Roncali L,
and Dammacco F (1999). Human erythropoietin induces a pro-angiogenic phe-
notype in cultured endothelial cells and stimulates neovascularization in vivo.
Blood 93, 2627–2636.
[18] Zhande R and Karsan A (2007). Erythropoietin promotes survival of primary
human endothelial cells through PI3K-dependent, NF-kappaB–independent
upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol 292, H2467–H2474.
[19] Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-
Rihm C, Martin H, Zeiher AM, and Dimmeler S (2003). Erythropoietin is a
potent physiologic stimulus for endothelial progenitor cell mobilization. Blood
102, 1340–1346.
[20] Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T,
Boehm SM, Menne J, Haller H, and Fliser D (2004). Erythropoietin regulates
endothelial progenitor cells. Blood 103, 921–926.
[21] Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig
B, Marks W, Witte L, et al. (2001). Impaired recruitment of bone-marrow–
derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis
and growth. Nat Med 7, 1194–1201.
[22] Bertolini F, Shaked Y, Mancuso P, and Kerbel RS (2006). The multifaceted cir-
culating endothelial cell in cancer: towards marker and target identification. Nat
Rev Cancer 6, 835–845.
[23] Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, and
Okumura K (2002). Critical role for tumor necrosis factor–related apoptosis-
inducing ligand in immune surveillance against tumor development. J Exp
Med 195, 161–169.
[24] Okazaki T, Ebihara S, AsadaM, Yamanda S, Saijo Y, Shiraishi Y, Ebihara T,Niu K,
Mei H, Arai H, et al. (2007). Macrophage colony-stimulating factor improves
cardiac function after ischemic injury by inducing vascular endothelial growth
factor production and survival of cardiomyocytes. Am J Pathol 171, 1093–1103.
[25] Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis
and metastasis—correlation in invasive breast carcinoma.N Engl J Med 324, 1–8.
[26] Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya
S, and Taketo MM (2002). Cyclooxygenase 2– and prostaglandin E(2) receptor
EP(2)–dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Can-
cer Res 62, 506–511.
[27] Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, Hashimoto
H, Mak TW, Yagita H, Okumura K, et al. (2001). Critical roles of TRAF2 and
TRAF5 in tumor necrosis factor–induced NF-kappa B activation and protection
from cell death. J Biol Chem 276, 36530–36534.
[28] Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, Piao JH, Yagita
H, Okumura K, Doi T, et al. (2003). NF-kappaB inhibits TNF-induced accu-
mulation of ROS that mediate prolonged MAPK activation and necrotic cell
death. EMBO J 22, 3898–3909.
[29] Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, and Noguchi
CT (2000). Erythropoietin stimulates proliferation and interferes with differen-
tiation of myoblasts. J Biol Chem 275, 39754–39761.
[30] Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten
H, Fichtlscherer S, Martin H, and Zeiher AM (2001). HMG-CoA reductase
inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt
pathway. J Clin Invest 108, 391–397.
[31] Ribatti D, Vacca A, Roccaro AM, Crivellato E, and Presta M (2003). Erythro-
poietin as an angiogenic factor. Eur J Clin Invest 33, 891–896.
[32] Ghezzi P and Brines M (2004). Erythropoietin as an antiapoptotic, tissue-
protective cytokine. Cell Death Differ 11 (Suppl 1), S37–S44.
[33] Mori M, Uchida M, Watanabe T, Kirito K, Hatake K, Ozawa K, and Komatsu
N (2003). Activation of extracellular signal–regulated kinases ERK1 and ERK2
induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoie-
tin signaling. J Cell Physiol 195, 290–297.
[34] Asahara T, Takahashi T,Masuda H, Kalka C, ChenD, IwaguroH, Inai Y, SilverM,
and Isner JM (1999). VEGF contributes to postnatal neovascularization by mobi-
lizing bone marrow–derived endothelial progenitor cells. EMBO J 18, 3964–3972.
[35] Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM,
and Dimmeler S (2001). Number and migratory activity of circulating endothe-
lial progenitor cells inversely correlate with risk factors for coronary artery dis-
ease. Circ Res 89, E1–E7.
[36] Rafii S and Lyden D (2003). Therapeutic stem and progenitor cell transplanta-
tion for organ vascularization and regeneration. Nat Med 9, 702–712.
[37] Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, and Salven P
(2004). Adult bone marrow–derived cells recruited during angiogenesis com-
prise precursors for periendothelial vascular mural cells. Blood 104, 2084–2086.
[38] Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van
G, and Begley CG (2006). Anti–Epo receptor antibodies do not predict Epo
receptor expression. Blood 107, 1892–1895.
Neoplasia Vol. 10, No. 9, 2008 Epo Promotes Growth of Tumors Lacking Its Receptor Okazaki et al. 939
